A landmark trial found that Wegovy reduced major adverse cardiovascular events including heart attack and stroke by approximately 20% in people with obesity and existing cardiovascular disease
NICE recommends that: Pharmacological treatment should only be used as part of a comprehensive weight management programme Medications should be prescribed only when licensed and evidence-based Very low-calorie diets (VLCDs, 800 kcal/day) may be considered for specific patients under specialist supervision, but should be time-limited and nutritionally complete Wegovy is recommended by NICE (TA875) for specific patient groups: adults with a BMI of at least 35 kg/m (or 30 kg/m with weight-related comorbidities), who have at least one weight-related comorbidity and have completed a tier 3 service
For some people, medication may be an appropriate starting point
A year after stopping, they were still down about 6% from their starting weight, compared with about 3% in those who didnt receive additional support
A microRNA cluster controls fat cell differentiation and adipose tissue expansion by regulating SNCG
Evita reas con enrojecimiento, irritacin o cicatrices
.jpg)
